Person:
ÖZEL, FURKAN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÖZEL

First Name

FURKAN

Name

Filters

20221
Reset filters

Settings

Author: LÜLECİ, NİMET EMEL ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Changes in the etiology of chronic liver disease by referral to a fibroscan center: rising prevalence of the non-alcoholic fatty liver disease” hepatology
    (2022-12-01) ÖZEL, FURKAN; LÜLECİ, NİMET EMEL; Eris T., Hassan M., Hikal Y., Sawah E., Daneshgar F., TEKER SAYIN A. G., ÖZEL F., LÜLECİ N. E., Kaya E., YILMAZ Y.
    Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with wide etiological spectrum. FibroScan® is used for follow-up of fibrosis and steatosis. This single center study aims to review the distribution of indications by referral to FibroScan®. Materials and Methods: Demographic characteristics, CLD etiologies, and FibroScan® parameters of the patients, who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated. Results: Out of 9,345 patients, 4,946 (52.9%) were male, and median age was 48 [18-88]. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N= 4,768, 51.02%) followed by hepatitis B (N=3,194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, CLD etiology, the results revealed that patients with older age (Odds ratio (OR) =2.908, confidence interval (CI): 2.597-3.256, P<0.001), and patients with hepatitis C (OR= 2.582; CI=2.168-3.075; P<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, P<0.001), autoimmune hepatitis (OR=2.138; CI=1.360-3.660, P<0.001) had increased odds of advanced liver fibrosis compared to NAFLD. Conclusion: NAFLD was the most common indication for referral to FibroScan®.